SG11201501460RA - Correctly folded etanercept in high purity and excellent yield - Google Patents

Correctly folded etanercept in high purity and excellent yield

Info

Publication number
SG11201501460RA
SG11201501460RA SG11201501460RA SG11201501460RA SG11201501460RA SG 11201501460R A SG11201501460R A SG 11201501460RA SG 11201501460R A SG11201501460R A SG 11201501460RA SG 11201501460R A SG11201501460R A SG 11201501460RA SG 11201501460R A SG11201501460R A SG 11201501460RA
Authority
SG
Singapore
Prior art keywords
high purity
correctly folded
excellent yield
folded etanercept
etanercept
Prior art date
Application number
SG11201501460RA
Other languages
English (en)
Inventor
Tsutomu Arakawa
Douglas Farrar
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201501460R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of SG11201501460RA publication Critical patent/SG11201501460RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201501460RA 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield SG11201501460RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Publications (1)

Publication Number Publication Date
SG11201501460RA true SG11201501460RA (en) 2015-04-29

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501460RA SG11201501460RA (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Country Status (33)

Country Link
US (6) US20140072560A1 (enExample)
EP (1) EP2895188B1 (enExample)
JP (3) JP2015533797A (enExample)
KR (2) KR102250937B1 (enExample)
CN (2) CN110051823A (enExample)
AR (1) AR092532A1 (enExample)
AU (2) AU2013315750B9 (enExample)
BR (1) BR112015005161A2 (enExample)
CA (1) CA2882551A1 (enExample)
CL (1) CL2015000572A1 (enExample)
CO (1) CO7400876A2 (enExample)
CY (1) CY1120062T1 (enExample)
DK (1) DK2895188T3 (enExample)
DO (1) DOP2015000055A (enExample)
EA (1) EA031324B1 (enExample)
EC (1) ECSP15014138A (enExample)
ES (1) ES2657377T3 (enExample)
HR (1) HRP20180182T1 (enExample)
HU (1) HUE036524T2 (enExample)
IL (2) IL237311B (enExample)
IN (1) IN2015KN00452A (enExample)
LT (1) LT2895188T (enExample)
MX (2) MX360044B (enExample)
NO (1) NO2972131T3 (enExample)
PE (2) PE20150996A1 (enExample)
PL (1) PL2895188T3 (enExample)
PT (1) PT2895188T (enExample)
RS (1) RS57013B1 (enExample)
SG (1) SG11201501460RA (enExample)
SI (1) SI2895188T1 (enExample)
SM (1) SMT201800163T1 (enExample)
TW (2) TWI716649B (enExample)
WO (1) WO2014043103A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
HK1200718A1 (en) 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
PE20150996A1 (es) * 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
CN106536565A (zh) * 2014-06-13 2017-03-22 鲁宾有限公司 一种用于纯化TNFR‑Fc融合蛋白的方法
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
BR112017014224A2 (pt) 2014-12-31 2018-03-06 Lg Chem, Ltd. método para a preparação de proteína de fusão fc-tnfr que contém teor alvo de impurezas
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
RU2018121657A (ru) * 2015-11-18 2019-12-19 Мерк Патент Гмбх ПРОТИВОПОЛОЖНЫЕ ГРАДИЕНТЫ pH-СОЛЬ ДЛЯ УЛУЧШЕННОГО РАЗДЕЛЕНИЯ БЕЛКОВ
AU2016355739A1 (en) * 2015-11-18 2018-07-05 Merck Patent Gmbh Improved protein separation in ion exchange chromatography
KR20250107275A (ko) * 2016-06-17 2025-07-11 제넨테크, 인크. 다중 특이적 항체의 정제
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CN110582510B (zh) * 2017-03-24 2023-09-15 科学与工业研究委员会 用于纯化重组抗体片段的方法
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
JP2023523823A (ja) 2020-05-01 2023-06-07 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー タンパク質の精製の改善されたプロセス
WO2022195505A1 (en) * 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DE10075010I2 (de) 1990-06-28 2004-01-29 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung.
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
JP2005505494A (ja) 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加
EP1478394B1 (en) 2002-02-27 2008-07-30 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
RS51041B (sr) 2003-02-28 2010-10-31 Ares Trading S.A. Tečne formulacije tbp-1 proteina koji vezuju faktor tumorske nekroze
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
CN100509847C (zh) 2003-08-01 2009-07-08 安美基公司 结晶肿瘤坏死因子受体2多肽
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
CA2552639C (en) * 2004-02-27 2012-05-01 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
AU2005229359C1 (en) 2004-03-05 2011-07-28 Patheon Holdings I B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006132363A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
KR101378194B1 (ko) 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
SG170750A1 (en) 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
US20080003220A1 (en) 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
TW200831129A (en) 2006-10-06 2008-08-01 Amgen Inc Stable formulations
TW200833357A (en) 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
HUE026403T2 (en) 2007-03-02 2016-06-28 Wyeth Llc Use of copper and glutamate in cell culture to produce polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
LT2170390T (lt) 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
WO2009146755A1 (en) * 2008-06-05 2009-12-10 Affibody Ab Polypeptide
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
WO2011017514A1 (en) 2009-08-07 2011-02-10 Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
RU2644651C2 (ru) 2010-04-26 2018-02-13 Новартис Аг Среда для культивирования клеток
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
JP2013536683A (ja) 2010-08-31 2013-09-26 フリエスランド ブランズ ビー．ブイ． 真核細胞のための培養培地
MX344268B (es) * 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
WO2012143418A1 (en) 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
AU2012279205B2 (en) 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
IL288509B2 (en) 2011-07-01 2023-04-01 Amgen Inc Mammalian cell culture
BR112014000352A2 (pt) * 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
EP2753634B1 (en) * 2011-08-17 2017-11-01 Ares Trading S.A. Method for preparing active form of tnfr-fc fusion protein
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
HK1200718A1 (en) * 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
WO2014011672A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
PE20150996A1 (es) * 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
JP6757311B2 (ja) * 2014-07-31 2020-09-16 エムティティ イノベーション インコーポレイテッドＭｔｔ Ｉｎｎｏｖａｔｉｏｎ Ｉｎｃｏｒｐｏｒａｔｅｄ フリーフォームレンジングのための数値的アプローチ、エリアパラメータ化フリーフォームレンジング
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
DOP2015000055A (es) 2015-04-30
CN110051823A (zh) 2019-07-26
MX2018012749A (es) 2020-11-12
HUE036524T2 (hu) 2018-07-30
SMT201800163T1 (it) 2018-05-02
KR20200085937A (ko) 2020-07-15
US11001627B2 (en) 2021-05-11
IL237311B (en) 2019-07-31
BR112015005161A2 (pt) 2017-07-04
AU2018247244A1 (en) 2018-11-01
US10947306B2 (en) 2021-03-16
AR092532A1 (es) 2015-04-22
JP2019038817A (ja) 2019-03-14
PT2895188T (pt) 2018-02-08
MX360044B (es) 2018-10-19
LT2895188T (lt) 2018-04-10
EA031324B1 (ru) 2018-12-28
US20190300600A1 (en) 2019-10-03
IL267452B (en) 2021-05-31
JP6913066B2 (ja) 2021-08-04
KR20150056601A (ko) 2015-05-26
US10954293B2 (en) 2021-03-23
IL267452A (en) 2019-08-29
IN2015KN00452A (enExample) 2015-07-17
KR102133699B1 (ko) 2020-07-14
EP2895188B1 (en) 2017-11-15
WO2014043103A1 (en) 2014-03-20
TWI716649B (zh) 2021-01-21
AU2013315750B2 (en) 2018-07-12
TWI609877B (zh) 2018-01-01
ECSP15014138A (es) 2016-01-29
PE20150996A1 (es) 2015-08-01
HRP20180182T1 (hr) 2018-04-20
TW201803593A (zh) 2018-02-01
ES2657377T3 (es) 2018-03-05
US20180037642A1 (en) 2018-02-08
CY1120062T1 (el) 2018-12-12
US20190300601A1 (en) 2019-10-03
CL2015000572A1 (es) 2016-02-05
US20140072560A1 (en) 2014-03-13
CO7400876A2 (es) 2015-09-30
US10954294B2 (en) 2021-03-23
JP2015533797A (ja) 2015-11-26
CN104902914A (zh) 2015-09-09
EP2895188A4 (en) 2016-05-25
PL2895188T3 (pl) 2018-06-29
CN104902914B (zh) 2019-01-01
US20190300602A1 (en) 2019-10-03
EP2895188A1 (en) 2015-07-22
DK2895188T3 (en) 2018-02-26
JP2021100929A (ja) 2021-07-08
CA2882551A1 (en) 2014-03-20
US10954295B2 (en) 2021-03-23
TW201425331A (zh) 2014-07-01
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (enExample) 2018-04-21
US20190330325A1 (en) 2019-10-31
PE20200607A1 (es) 2020-03-10
SI2895188T1 (en) 2018-05-31
AU2013315750A1 (en) 2015-03-05
RS57013B1 (sr) 2018-05-31
AU2018247244B2 (en) 2020-05-28
MX2015003090A (es) 2015-07-14
AU2013315750B9 (en) 2018-11-15
EA201590542A1 (ru) 2015-07-30
IL237311A0 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
IL267452B (en) Ethanercept is correctly folded with a high degree of cleanliness and excellent utilization
GB2499314B (en) Replacement-gate finfet structure and process
ZA201500231B (en) Photovoltaic frame fastener
GB201201506D0 (en) Photovoltaic panel circuitry
GB2509046B (en) Improvement in or relating to capsules
EP2855745A4 (en) METHODS RELATING TO ADALIMUM AB
EP2932375A4 (en) ADAPTATION OF OPPORTUNITY IN CONTEXT
EP2806761A4 (en) COMPONENTS OF A SEASACK
PL2806773T3 (pl) Moduł do zaparzania
PT2888284T (pt) Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
IL235425B (en) History of lysine-glutamic acid di-peptide
IL239824A0 (en) Use of inos inhibitors to increase viral survival in culture
EP2888277A4 (en) ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ZA201503367B (en) Heteroaryl derivatives and uses thereof
GB2503225B (en) Balun
GB201210817D0 (en) Balun
EP2909309A4 (en) COMPOSITIONS AND METHODS FOR VITAMINOUS FERMENTATES
PT2906528T (pt) Processo para a obtenção de anilina pura
AU343220S (en) Zipper securing aid
AU343221S (en) Zipper securing aid
ZA201504198B (en) Methods for banana yield protection and enhancement
HUP1200259A2 (en) Shopping bag which can also be as litterbag
GB201201013D0 (en) Sleeping bag
IL212583A0 (en) Marketng by means of placing independent show cascs in shopping cenlers
GB201220447D0 (en) Releasable fastener